74 results about "Murine leukemia virus" patented technology

We have made retrovirus particles displaying a functional antibody fragment. We fused the gene encoding an antibody fragment directed against a hapten with that encoding the viral envelope protein (Pr80env) of the ecotropic Moloney murine leukemia virus. The fusion gene was co-expressed in ecotropic retroviral packaging cells with a retroviral plasmid carrying the neomycin phosphotransferase gene (neo), and retroviral particles with specific hapten biding activities were recovered. Furthermore the hapten-binding particles were able to transfer the neo gene and the antibody-envelope fusion gene to mouse fibroblasts. In principle, the display of antibody fragments on the surface of recombinant retroviral particles could be used to target virus to cells for gene delivery, or to retain the virus in target tissues, or for the construction of libraries of viral display packages.

The compounds, pharmaceutical compositions, and methods of using such compounds or compositions thereof described herein are useful for treating a disease modulated by B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein expression.

The present invention discloses Moloney murine leukemia virus (MoMLV)-based viral packaging cell line for the production of anti-viral vaccines. The invention also includes methods of making, administering and formulating pseudovirions and replicon deficient viral particles of the invention and methods of inducing immunity.

The invention relates to the production and use of retroviral vectors for cell specific gene transfer, specially to a production method of retroviral vectors containing capsid particles of murine leukemia virus (MLV) and envelope proteins of human immunodeficiency vises (HIV) or simian immunodeficiency viruses (SIV). Said vectors can be used for gene transfer in selected cell types, specially in CD4-positive mammal cells.

Provided is a composition for reprogramming somatic cells to generate embryonic stem cell-like cells, comprising: a) a Bmi1 (B cell-specific Moloney murine leukemia virus integration site 1) protein or a nucleic acid molecule encoding the Bmi1 protein; and b) at least one low molecular weight substance selected from the group consisting of a set of a MEK/ERK (mitogen-activated protein kinase/extracellular regulated kinase) inhibitor and a GSK (glycogen synthase kinase) inhibitor, a set of a G9a HMTase (G9a histone methyltransferase) inhibitor and a DMNT (DNA methyltransferase) inhibitor, and a histone deacetylase inhibitor. Also, a method is provided for reprogramming somatic cells to generate embryonic stem cell-like cells using the composition. In addition to reducing the number of the reprogramming factors conventionally needed, the composition and method allow the generation of pluripotent embryonic stem cell-like cells which have high potential in the cell therapy of various diseases.

Murine leukemia virus (MLV) and lentivirus vectors have been used previously to deliver genes to hematopoietic stem cells (HSCs) in human gene therapy trials. However, these vectors integrate randomly into the host genome, leading to disruption or inactivation of vital host genes. The present invention discloses a novel lentiviral vector system that overcomes this problem by integrating into a host genome in a site-specific manner.

The invention relates to an avian influenza H7N9 virus RT-PCR (reverse transcription-polymerase chain reaction) detecting kit and a detecting method, and aims at providing the detecting kit which has the characteristics of convenience in use and accuracy in detection, and the detecting method which has the characteristics of high accuracy, simplicity and convenience in detection. The technical scheme is as follows: the avian influenza H7N9 virus fluorescence-quantitative RT-PCR detecting kit comprises deoxynucleotide triphosphate, MgCl2, an RT-PCR buffer solution, an avian influenza H7N9 virogene standard product, an RNA (Ribonucleic Acid) enzyme inhibitor, an MMLV (Moloney Murine Leukemia Virus) reverse transcriptase and a DNA (Deoxyribonucleic Acid) polymerase, and is characterized in that the detecting kit also comprises an upstream primer, a downstream primer and a specific probe. The avian influenza H7N9 virus fluorescence-quantitative RT-PCR detecting method comprises the following steps of: (1) extracting RNA of a sample to be detected; (2) carrying out RT-PCR reaction; and (3) carrying out fluorescence detection on the RT-PCR reaction product.

The present invention provides a safe and highly efficient retroviral vector derived from the MLV (murine leukemia virus) for use in gene therapy, which lacks viral coding sequences but contains the genetically engineered EF Iα non-coding sequence harboring splicing acceptor.

The invention relates to a method for preparing a visual classical swine fever virus (CSFV) gene detection reagent based on G4DNAzyme coloration. The method comprises the following steps: selecting cells infected with viruses, after freeze thawing and lysing, adopting a gene extraction kit for extracting a target gene and obtaining cDNA after carrying out reverse transcription and inactivation onMoloney murine leukemia virus (MMLV) reverse transcriptase; adding the cDNA to an asymmetric polymerase chain reaction (PCR) system and obtaining an asymmetric PCR product through degeneration, annealing and extension amplification for 50-100 cycles; and adding upstream and downstream probes and the asymmetric PCR product to G4DNAzyme coloration reaction buffer, and after degeneration and annealing, adding Hemin, ATBS and H2O2 to carry out coloration reaction and observing whether macroscopic green color appears, thus judging whether CSFV infection exists. The method has the beneficial effects of high detection speed, accuracy, stability, good repeatability, simple and easy-to-operate detection steps, capability of directly observing the coloration reaction with naked eyes, intuitionisticresults and low cost.

The invention discloses a standard product which is used for detecting the viral load of Friend murine leukemia, and a method which detects the viral load of the Friend murine leukemia by a real-time fluorescent quantitative polymerase chain reaction method (Real-Time RT-PCR method) by using the standard product. The detection process includes the steps of the extraction and content measurement of leukovirus nucleic acid (RNA), the obtaining of the nucleic acid segment by amplifying reverse transcription by using a primer, the detection of the real-time fluorescent quantitative polymerase chain reaction (Real-time PCR), and the like. Compared with conventional PCR detection methods, the method of the invention, which detects the viral load of the Friend murine leukemia, has better specificity. The detected genetic amplified products are target genetic products to be detected. The method has a better linear relationship and is suitable for being applied to the detection of the viral load of the Friend murine leukemia (Fr. MuLV).

The invention relates to an expression and purification of murine leukemia virus reverse transcriptase (MMLV-RT), in particular to a soluble expression and a purification method for recombinant murineleukemia virus reverse transcriptase (MMLV-RT), which belongs to the field of biochemistry. MMLV-RT genes and enterokinase restriction enzyme cutting sites are cloned in a pET28a vector through vector construction; the MMLV-RT and molecular chaperones are co-expressed at the low temperature; the expression amount of protein is improved to 15 percent; and the solubility of the protein is 10 timesthat of the protein expressed by a conventional method.

The present invention provides a chimeric HIV-1 construct, EcoHIV, capable of replication in a rodent cell. The invention also provides a convenient and safe rodent model of HIV-1 infection and AIDS. Methods for producing a rodent model of HIV-1 infection are also provided. Additionally, the invention provides the means to test immunogenic compositions or pharmaceutical interventions effective in preventing infection, reducing viral load, or reducing disease symptoms in a subject.

The invention relates to a method for detecting nucleic acid of a porcine reproductive and respiratory syndrome (PRRS) virus by one step, which comprises the following steps of: collecting, processing and detecting samples, wherein in the collecting step, an animal blood sample is dripped into a full type approval (FTA) card sample area; and the detecting steps comprises the: (1) designing specific primers and a probe for general type PRRS virus, and marking carboxyfluorescein (FAM) and tetramethyl rhodamine (TAMARA) fluorescent groups on the probe; and (2) preparing and optimizing a detection system and a reaction condition, wherein a reaction system comprises 25 or 50 microliters of trihydroxymethyl aminomethane-hydrogen chloride (HCl) (the pH value is between 7.8 and 9.0), 0.1 to 0.5 micro mol of upstream primer and 0.1 to 0.5 micro mol of downstream primer, 100 to 400 micro mols of deoxynucleotide mixture, 0.1 to 0.5 micro mol of probe, 100 to 300 U of Moloney murine leukemia virus (M-MLV) reverse transcriptase, 1 to 5 U of thermostable deoxyribonucleic acid (DNA) polymerase, 4 to 8 mols of Mg<2+->, 300 to 500 nano mol of homogenized reference dyes ROX, and 1 to 15 microliters of sample which is re-suspended in trihydroxymethyl aminomethane-ethylene diamine tetraacetic acid (EDTA) buffer solution and is added before each time of reaction. In the method, the sample collection is easy and convenient, so that an FTA card containing s ribonucleic acid (RNA) sample can be posted to any one central laboratory to be detected according to a form of regular mails; and the pollution risks are reduced, and the detection sensitivity is improved.

The present invention relates to an Abelson murine leukaemia viral oncogene homolog 1 (ABL1) inhibitor for use in the treatment of ocular neovascularisation associated with a non-cancerous condition. The invention also relates to the use of an ABL1 inhibitor as a complementary therapy with VEGF or VEGF receptor inhibitor treatment and provides pharmaceutical compos itions and kits comprising one or both inhibitors.

The invention relates to an avian influenza virus H7 type RT-PCR (reverses transcription-polymerase chain reaction) detecting kit and a detecting method, and aims at providing the detecting kit which has the characteristics of convenience in use and accuracy in detection, and the detecting method which has the characteristics of high accuracy, simplicity and convenience in detection. The technical scheme is as follows: the avian influenza virus H7 type fluorescence-quantitative RT-PCR detecting kit comprises deoxynucleotide triphosphate, MgCl2, an RT-PCR buffer solution, an avian influenza virus H7 gene standard product, an RNA (Ribonucleic Acid) enzyme inhibitor, an MMLV (Moloney Murine Leukemia Virus) reverse transcriptase and a DNA (Deoxyribonucleic Acid) polymerase, and is characterized in that the fluorescence-quantitative RT-PCR detecting kit also comprises an upstream primer, a downstream primer and a specific probe. The avian influenza virus H7 type fluorescence-quantitative RT-PCR detecting method comprises the following steps of: (1) extracting RNA of a sample; (2) carrying out RT-PCR reaction; and (3) carrying out fluorescence detection on the RT-PCR reaction product.

The invention discloses an HBV (hepatitis B virus) real-time fluorescent nucleic acid isothermal amplification detection kit, comprising a capture probe, an HBV primer, a primer T7 and a primer nT7, an HBV detection probe, an M-MLV (Moloney Murine Leukemia Virus) reverse transcriptase, polymerase T7RNA and the like reagents. A method of the invention enables high-specificity high-sensitivity low-pollution quick nucleic acid amplification detection for serum or plasma samples containing hepatitis B virus, has the advantages of high detection efficiency and high accuracy, can detect A-I 9 genotypes of HBV and has a promising application prospect.

The invention relates to a detection kit and a detection method of reverse transcription polymerase chain reaction (RT-PCR) of an avian influenza virus N9, and aims at providing the detection kit and the detection method, wherein the provided detection kit has the characteristics of being convenient to use and accurate to detect; and the provided method has the characteristics of being high in detection accuracy, and simple and convenient to detecting process. The technical scheme is as follows: the detection kit of fluorescent quantitative RT-PCR of the avian influenza virus N9 comprises deoxy triphosphate nucleoside, MgCl2, RT-PCR buffer solution, an avian influenza virus N9 genetic standard, a ribonucleic acid (RNA) enzyme inhibitor, moloney murine leukemia virus (MMLV) reverse transcriptase and deoxyribonucleic acid (DNA) polymerase. The detection kit of fluorescent quantitative RT-PCR is characterized by also comprising an upstream primer, a downstream primer and a specific probe. The detection method of fluorescent quantitative RT-PCR of the avian influenza virus N9 is carried out according to the following steps of: (1) extracting the RNA; (2) carrying out RT-PCR; and (3) carrying out fluorescence detection on an RT-PCR reaction product.

Disclosed is a composition for reprogramming somatic cells to generate embryonic stem cell-like cells, comprising: a) a Bmi1 (B cell-specific Moloney murine leukemia virus integration site 1) protein or a nucleic acid molecule coding for Bmi1; and b) an Oct4 protein or a nucleic acid molecule coding for Oct4. Also, a method is provided for reprogramming somatic cells to generate embryonic stem cell-like cells using the composition. In addition to reducing the number of the genetic factors conventionally needed, the composition and method allow the generation of pluripotent embryonic stem cell-like cells which have high potential in the cell therapy of various diseases.

Methods of detecting, diagnosing, monitoring or managing an XMRV-related neuroimmune disease such as chronic fatigue syndrome or XMRV-related lymphoma such as mantle cell lymphoma in a subject are disclosed. These methods comprise determining presence, absence or quantity an XMRV nucleic acid in a sample from a subject.